Meridian Bioscience, Inc., a life science company, develops, manufactures, sells, and distributes clinical diagnostic test kits primarily for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company's diagnostic products principally include C. difficile for the detection of gastrointestinal diseases, such as antibiotic-associated diarrhea; Rotavirus and Adenovirus products for pediatric diarrhea detection; H. pylori for the detection of stomach ulcers; EHEC test for the detection of Enterohemorrhagic E. coli infection and Campy for the detection of Campylobacter jejuni; and Group A Strep and Group B Strep tests for the detection of streptococcus bacterial infections. Its diagnostic products are also used in the detection of viral diseases, such as mononucleosis, herpes simplex, chicken pox, and shingles; organ transplant infections; parasitic diseases, including giardiasis, cryptosporidiosis, and lyme; and respiratory diseases, such as pneumonia, valley fever, influenza, and respiratory syncytial virus. The company also offers transport media that store and preserve specimen samples from patient collection to laboratory testing; and bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic companies. In addition, it engages in the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines; and sale and distribution of diagnostic test kits manufactured by third-party vendors. The company markets its products through direct sales force and independent distributors primarily to hospitals, reference laboratories, and research customers in the United States, Asia, Canada, South America, Australia, Europe, Africa, and the Middle East. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.